Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Neurodegenerative diseases constitute a heterogeneous group of age-related disorders that are characterized by a slow but irreversible deterioration of brain functions. Evidence accumulated over more than two decades has implicated calcium-related homeostatic mechanisms, giving rise to the Ca(2+) hypothesis of brain aging and, ultimately, cell death. Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter within the central (CNS), peripheral and enteric nervous systems. It appears to be involved in a wide variety of physiological functions within and outside the nervous system, that are maintained through a complex interaction between GABA and calcium-dependent neurotransmission and cellular metabolic functions. Within CNS the Ca(2+)/GABA mechanism stabilizes neuronal activity both at cellular and systemic levels. Decline in the Ca(2+)/GABA control initiates several cascading processes leading to both weakened protective barriers (in particular the blood-brain barrier) and accumulations of intracellular deposits of calcium and Lewy bodies. Linking such a vital mechanism of synaptic transmission with metabolism (both at cellular and tissue level) by means of a common reciprocal Ca(2+)/GABA inhibition results in a fragile balance, which is prone to destabilization and auto-destruction. The GABA decline etiology proposed here appears to apply to all human neurodegenerative processes initiated by abnormal intracellular calcium levels. Therefore, the original description of Parkinson's disease (PD) as due to the selective damage of dopaminergic neurons in the mesencephalon should be updated into the concept of a severe multisystemic neurodegenerative disorder of the nervous system, whose clinical symptoms reflect the localization and progression of the most advanced GABA pathology. A future and more complete therapeutic approach to PD should be aimed first at slowing (or stopping) the progression of Ca(2+)/GABA functional decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Pathological inclusions are thought to form in a small number of cells and-given enough time and, perhaps, a genetic predisposition-spread in a deterministic manner to distant brain regions (Braak et al., 2003, 2004; Goedert, 2015).”
BackgroundStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
The blood-brain barrier/neurovascular unit in health and disease
Hawkins, B. T., & Davis, T. P. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.4 · Cited by 2,661
-Synuclein in Parkinson's Disease
Stefanis, L. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009399 · Cited by 1,446 · cited 4×
“…have non-motor symptoms such as a decreased sense of smell, depression, and various gastrointestinal and other systemic features, which have been shown to predate the classical motor features of PD (Pellicano et al., 2007; Stefanis, 2012), and which are undoubtedly related to the deficit of GABA.”
BackgroundInfluentialArizona Parkinson’s Disease Consortium, Beach, T. G., Adler, C. H., Sue, L. I., Vedders, L., Lue, L., White III, C. L., Akiyama, H., Caviness, J. N., Shill, H. A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0664-3 · Cited by 911
Premotor Parkinson’s disease: Concepts and definitions
Siderowf, A., & Lang, A. E. (2012) · Movement Disorders · doi:10.1002/mds.24954 · Cited by 174
Cited by
Maiti, P., Manna, J., & Dunbar, G. L. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0099-z · Cited by 525
Oral administration of Proteus mirabilis damages dopaminergic neurons and motor functions in mice
Choi, J. G., Kim, N., Ju, I. G., Eo, H., Lim, S.-M., Jang, S.-E., Kim, D.-H., & Oh, M. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19646-x · Cited by 170
Althaus, A. L., Ackley, M. A., Belfort, G. M., Gee, S. M., Dai, J., Nguyen, D. P., Kazdoba, T. M., Modgil, A., Davies, P. A., Moss, S. J., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108333 · Cited by 135
Association between depression and the subsequent risk of Parkinson's disease: a meta-analysis
Wang, S., Mao, S., Xiang, D., & Fang, C. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.05.025 · Cited by 128
Inhibitory motor dysfunction in parkinson's disease subtypes
Gong, T., Xiang, Y., Saleh, M. G., Gao, F., Chen, W., Edden, R. A. E., & Wang, G. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25865 · Cited by 44
Metadata
- Authors
- Błaszczyk, J. W.
- Venue
- Frontiers in Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2016-06-09
- Volume
- 10
- Pages
- 269-269
- ISSN
- 1662-453X (ISSN-L)
- OpenAlex
- W2415368356
- Cited by
- 185
- References
- 6
- FWCI
- 8.15
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis. https://app.cochat.ai/papers/10.3389/fnins.2016.00269
- The paper
- Błaszczyk, J. W. (2016). Parkinson's Disease and Neurodegeneration: GABA-Collapse Hypothesis. Frontiers in Neuroscience. https://doi.org/10.3389/fnins.2016.00269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.